The Inflation Reduction Act (IRA) of 2022 contains a number of health care provisions, including those that will cut Medicare drug spending by an estimated $287 billion over 10 years, according to the congressional budget office. Some of the most widely discussed changes are several near-term changes to the Medicare Part D benefit that are some of the most significant changes in Medicare regulation since the Medicare Modernization Act of 2003. In this free brief (part 2 of 5), PRECISIONvalue expert Ryan Cox outlines how these cuts may impact access and affordability for all.

DOWNLOAD the free paper here!

Biosimilars are on track to reduce drug costs by $100 billion—but not everyone is on board. The Inflation Reduction Act has provisions that encourage their uptake. Get the details from PRECISIONvalue expert Amy Martin in this free brief (part 1 of 5).

DOWNLOAD the free paper here!

Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision’s Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.

READ THE ARTICLE HERE!

Since its release on November 30, 2022, ChatGPT has generated buzz across all corners of the internet and within every industry. The technology is likely to have in impact in healthcare, the life sciences, and marketing. Precision’s Marty Samples and others weigh in on its uses in healthcare and the life sciences, including its potential and potential pitfalls.

READ THE ARTICLE HERE!

Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.

CLICK HERE to read the full article